Condition: Hepatocellular Carcinoma · Squamous Cell Non-Small Cell Lung Cancer · Germ Cell Tumor · Sponsor: Zymeworks BC Inc.
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
This description comes directly from the study's public registry record.
Zymeworks Clinical Trial Resource · (206) 237-1030 · medinfo@zymeworks.com
Always discuss trial participation with your own doctor first.
| UCSF Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| University of California Los Angeles - Cancer Care - Santa Monica (UCLA) | Santa Monica, California, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| START - Dublin Mater Misericordiae University Hospital (MMUH) | Dublin, Ireland | Recruiting |
| National Cancer Center East | Kashiwa, Japan | Recruiting |
| Kyoto University Hospital | Kyoto, Japan | Recruiting |
| Kansai Medical University Hospital | Osaka, Japan | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07164313